Numbers

The Numbers

WW emerged from Chapter 11 in mid-2025 with a clean balance sheet — long-term debt fell from $1.43B to $465M and shareholder equity flipped from minus $4.1B to plus $318M — but the operating business is still shrinking faster than management can shrink the cost base. FY2025's headline net income of $1.06B is a non-cash gain on debt extinguishment; the underlying business produced $19M of operating income on $711M of revenue and burned $29M of cash. The stock then lost two-thirds of its value in the four months after the FY2025 print as 2026 guidance — revenue of $620–635M, down ~13% — confirmed that GLP-1 disruption is still grinding the core behavioural subscriber base lower. The single number that decides whether this re-rates is the trajectory of clinical (GLP-1-access) subscribers — currently ~130k and growing 42% year-over-year, but starting from a base too small to offset behavioural attrition.

Snapshot

Operating Health Scorecard

The table is the verdict in eight rows. Bankruptcy fixed the balance sheet but did not fix the business. A weight-management franchise that earned 30% operating margins in 2011 now earns 3% — that is not a cyclical valuation question; it is a business-model question.

Revenue & Earnings Power — 20-Year View

Revenue peaked at $1.84B in FY2012 — the post-Oprah-deal years pushed it briefly back above $1.5B in FY2018 — and has now retraced to $711M, the lowest since the early 1990s. Operating margin has been more dramatic: 30% in 2011, 20% on the 2017 Oprah bounce, and stuck in the low single digits or negative since 2022. Two distinct erosions are visible — the post-2014 brand fatigue, and the post-2022 GLP-1 disruption — and neither has reversed.

Quarterly Trajectory — Where Is the Bottom?

Sequential revenue has fallen for thirteen of the last sixteen quarters. Q4 FY2025 was the first uptick of the cycle — $175M vs. $172M in Q3 — but management's FY2026 guidance of $620–635M implies the first half of 2026 will revisit the $150M/quarter level. Until clinical-segment growth (GLP-1 telehealth access) becomes large enough to offset behavioural attrition, the trough is still ahead, not behind.

Cash Generation — Are the Earnings Real?

The two charts show the same story from different angles. Operating cash flow has crossed below zero just as net income spikes on the bankruptcy gain — a classic divergence telling you the income statement is unreliable. Capex has been throttled to under $1M for two years running, which keeps reported FCF respectable on a margin basis but means there is essentially no reinvestment in the platform, app, or clinical infrastructure that the company needs to compete in a GLP-1 world.

Capital Allocation — A Decade of Apology

WW has not paid a dividend since FY2013 and has effectively stopped buying back stock since 2018. The dominant capital outflow for a decade has been debt amortisation on the term loan stack — money that paid down legacy debt instead of building product. By 2022 even debt repayment stops, because the cash had run out: the term loan was kept current only through the bankruptcy filing of June 2025.

Balance Sheet — From Insolvent to Cleansed

This is the one chart where the news is unambiguously good. Net debt sat between $1.3B and $1.6B for fifteen years — at peak, leverage exceeded 7x EBITDA — then collapsed to $308M after restructuring. The new $465M term loan due 2028 is manageable on $100M of guided 2026 EBITDA. The risk is now operating, not financial.

Valuation — Now vs. Its Own 20-Year History

The valuation chart is the central exhibit. P/S of 0.41 is roughly a quarter of the 20-year median (1.66) — that looks like deep value at first glance. But EV/EBITDA at ~7x sits below the long-run 10x median by only one turn, and the EBITDA in the denominator has been engineered down to $87M from a $400M+ peak. The market is not mispricing the stock relative to the impaired earnings power; it is correctly recognising that the franchise has lost most of what it used to be worth.

Peers — One Table, the Right Lens

The peer set splits cleanly. HIMS is the GLP-1 winner — 64% three-year revenue CAGR and a 49x EBITDA multiple to match. Everyone else (WW, MED, BODI) is a wellness business with declining revenue and depressed multiples; HLF and USNA are MLM-style international franchises with different unit economics. WW's 3-year revenue CAGR of minus 12% is the worst of the legacy cohort, and its EV/EBITDA of 6.9x is materially above MED, BODI, and USNA — meaning WW is not even the cheapest weight-management asset in this universe. The premium is paid for the post-restructuring balance sheet and the optionality on the clinical pivot.

Fair Value — Bear / Base / Bull

At $9.80 the market is pricing somewhere between the bear and base. The asymmetry is real — bull case is roughly 3x current price; bear is a further 50% drawdown — but the dispersion sits almost entirely on one variable: whether the clinical/GLP-1-access subscriber line can grow large enough fast enough to flip total subscriber growth positive before the term loan refinancing window in 2028.

What to Watch

The numbers confirm the bankruptcy thesis: balance sheet is genuinely fixed, leverage is normal, debt service is covered. The numbers contradict the post-emergence "value" narrative — the cheap P/S is a function of impaired earnings, not market mispricing, and 2026 guidance points to another year of revenue decline. The single number to watch next quarter is end-of-period clinical subscribers (was 130k in Q4 FY2025); 200k+ by mid-FY2026 would suggest the GLP-1 pivot is working at scale and would re-rate the multiple. Anything below 160k means behavioural attrition is winning and the $620M revenue floor in guidance is not a floor.